TOL2, by Toleranzia AB

An effective and safe targeted therapy for the treatment of Myasthenia gravis (MG)

Myasthenia Gravis (MG) is a rare disease affecting 2 out of every 10,000 people. Despite being rare, MG is the most common chronic autoimmune neuromuscular disease. MG causes weakness in skeletal muscles, which are responsible for breathing and for moving all parts of the body, including arms and legs.

MG prevents patients from fully functioning in their daily activities, which often leads to unemployment and significantly reduces their quality of life. In addition, many of these patients may experience a myasthenic crisis, whose treatment is very expensive and which can lead to death. There is currently no cure for MG: there are more than 30 related clinical trials underway, but most of them are exclusively symptomatic treatments.

Our client, the Swedish company <em>Toleranzia AB</em>, is developing TOL2, an innovative therapy with great potential to cure MG: it will be the first MG therapy that induces long-term remission. TOL2 is based on a technology that uses the intrinsic power of the immune system to treat autoimmune diseases.

To carry out their project, Toleranzia AB applied to the November 2018 call for Phase 1 of the SME Instrument and we are pleased to announce that, after obtaining a score of 13.88, they obtained the necessary grant to carry out the tasks required in this phase.

We at Aristos are very pleased to have participated in this great achievement of <em>Toleranzia AB </em>and we wish them a great success in the development of their fantastic project, which can qualitatively improve, and even save, the lives of so many people.